The S&P 500 ticked 0.3% higher on Wednesday, July 16, 2025, as President Trump sought to ease concerns that a dismissal of ...

Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that ...

Johnson & Johnson (NYSE:JNJ) reported Q2 2025 earnings on July 16, 2025, posting sales of $23.7 billion (up 4.6%), with adjusted EPS of $2.77 and net earnings of $5.5 billion. Management raised ...

Johnson & Johnson shares surged Wednesday after the company reported second-quarter results that topped estimates and the company lifted its full-year outlook.

Food insecurity is not only linked with, but directly causes symptoms of anxiety and depression, according to research published in the open access ...

Adjusted earnings per share for the quarter to June 29 fell to $2.77 from $2.82 in the same period a year ago, and topped the ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

For decades, proponents of psychedelic drugs have come to Washington with a provocative message: Illegal, mind-altering substances like LSD and ecstasy should be approved for Americans grappling with ...

Johnson & Johnson (JNJ) has reportedly revised its forecast of the impact of U.S. President Donald Trump’s tariffs to $200 ...

Johnson & Johnson boosted its full-year outlook as it posted better-than-expected profit and sales in the second quarter. The healthcare-products company said Tuesday it now expects adjusted per-share ...

Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.